3-(3-(4-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-1-yl)benzylamino)benzoic acid | 1313803-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-(3-(4-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-1-yl)benzylamino)benzoic acid
• 英文别名: 3-[[3-[4-[4-(Trifluoromethyl)phenyl]benzimidazol-1-yl]phenyl]methylamino]benzoic acid
• CAS: 1313803-00-7
• 化学式: C₂₈H₂₀F₃N₃O₂
• 分子量: 487.481
• InChiKey: FMEFYYNWPMLLSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (9ci)-4-氯-1H-苯并咪唑 在 potassium phosphate 、 copper(l) iodide 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 sodium cyanoborohydride 、 potassium carbonate 、 对甲苯磺酸 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 72.0h， 生成 3-(3-(4-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-1-yl)benzylamino)benzoic acid
  参考文献：
  名称：

  Using ‘biased-privileged’ scaffolds to identify lysine methyltransferase inhibitors

  摘要：

  Methylation of histones by lysine methyltransferases (KMTases) plays important roles in regulating chromatin function. It is also now clear that improper KMTases activity is linked to human diseases, such as cancer. We report an approach that employs drug-like 'privileged' scaffolds biased with motifs present in S-adenosyl methionine, the cofactor used by KMTases, to efficiently generate inhibitors for Set7, a biochemically well-characterized KMTase. Setin-1, the most potent inhibitor of Set7 we have developed also inhibits the KMTase G9a. Together these data suggest that these inhibitors should provide good starting points to generate useful probes for KMTase biology and guide the design of KMTase inhibitors with drug-like properties. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.024

文献信息

• [EN] LYSINE AND ARGININE METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER<br/>[FR] INHIBITEURS DE LYSINE ET ARGININE MÉTHYLTRANSFÉRASE POUR LE TRAITEMENT DU CANCER
  申请人：UNIV ROCKEFELLER

  公开号：WO2011082098A1

  公开（公告）日：2011-07-07

  Compounds having lysine or arginine methyltransferase inhibitory activity and their use in the treatment of diseases and conditions associated with inappropriate methyltransferase activity are disclosed. The compounds are of the general formula (I).

  揭示了具有赖氨酸或精氨酸甲基转移酶抑制活性的化合物及其在治疗与不适当甲基转移酶活性相关的疾病和病况中的应用。这些化合物的一般公式为(I)。
• Using ‘biased-privileged’ scaffolds to identify lysine methyltransferase inhibitors
  作者：Sudhir Kashyap、Joel Sandler、Ulf Peters、Eduardo J. Martinez、Tarun M. Kapoor

  DOI：10.1016/j.bmc.2014.02.024

  日期：2014.4

  Methylation of histones by lysine methyltransferases (KMTases) plays important roles in regulating chromatin function. It is also now clear that improper KMTases activity is linked to human diseases, such as cancer. We report an approach that employs drug-like 'privileged' scaffolds biased with motifs present in S-adenosyl methionine, the cofactor used by KMTases, to efficiently generate inhibitors for Set7, a biochemically well-characterized KMTase. Setin-1, the most potent inhibitor of Set7 we have developed also inhibits the KMTase G9a. Together these data suggest that these inhibitors should provide good starting points to generate useful probes for KMTase biology and guide the design of KMTase inhibitors with drug-like properties. (C) 2014 Elsevier Ltd. All rights reserved.